Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Haleon Plc on October 3, 2024, for the month of October 2024. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). The filing serves as a Director Declaration pursuant to paragraph 6.4.9R of the Listing Rules.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory notification regarding board composition and does not contain financial performance data.
Material Changes
The primary material change disclosed is the departure of Alan Stewart from the Board of Diageo plc, effective September 26, 2024. This notification is required due to Haleon's historical relationship with Diageo prior to its spin-off.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a formal declaration of a director's resignation from a related entity's board.
Key Facts for Investors
- Alan Stewart stepped down from the Board of Diageo plc on September 26, 2024.
- This filing is a compliance notification under Listing Rules and does not include financial results.
- Haleon continues to operate as a global consumer health leader with major brands including Advil, Sensodyne, and Panadol.